These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16113688)

  • 1. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention.
    Ros J; Fernández-Varo G; Muñoz-Luque J; Arroyo V; Rodés J; Gunnet JW; Demarest KT; Jiménez W
    Br J Pharmacol; 2005 Nov; 146(5):654-61. PubMed ID: 16113688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.
    Jiménez W; Gal CS; Ros J; Cano C; Cejudo P; Morales-Ruiz M; Arroyo V; Pascal M; Rivera F; Maffrand JP; Rodés J
    J Pharmacol Exp Ther; 2000 Oct; 295(1):83-90. PubMed ID: 10991964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
    J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites.
    Fernández-Varo G; Ros J; Cejudo-Martín P; Cano C; Arroyo V; Rivera F; Rodés J; Jiménez W
    J Hepatol; 2003 Jun; 38(6):755-61. PubMed ID: 12763368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
    Gunnet JW; Matthews JM; Maryanoff BE; de Garavilla L; Andrade-Gordon P; Damiano B; Hageman W; Look R; Stahle P; Streeter AJ; Wines PG; Demarest KT
    Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):320-6. PubMed ID: 16620295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
    Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
    Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
    Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.
    Inoue T; Ohnishi A; Matsuo A; Kawai B; Kunihiro N; Tada Y; Koizumi F; Chau T; Okada K; Yamamura Y; Tanaka T
    Clin Pharmacol Ther; 1998 May; 63(5):561-70. PubMed ID: 9630829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats.
    Fernández-Varo G; Oró D; Cable EE; Reichenbach V; Carvajal S; de la Presa BG; Wiśniewski K; Ginés P; Harris G; Jiménez W
    Hepatology; 2016 Jan; 63(1):207-16. PubMed ID: 26403564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
    Decaux G
    J Lab Clin Med; 2001 Jul; 138(1):18-21. PubMed ID: 11433224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
    Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
    Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F; Blei AT; Blendis LM; Thuluvath PJ
    Hepatology; 2003 Jan; 37(1):182-91. PubMed ID: 12500203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of solute-free water retention in experimental ascitic cirrhosis: is vasopressin the only culprit?
    Sansoè G; Aragno M; Mastrocola R; Parola M
    Clin Sci (Lond); 2016 Jan; 130(2):117-24. PubMed ID: 26519424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
    Gerbes AL; Gülberg V; Ginès P; Decaux G; Gross P; Gandjini H; Djian J;
    Gastroenterology; 2003 Apr; 124(4):933-9. PubMed ID: 12671890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
    J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
    Ohnishi A; Orita Y; Okahara R; Fujihara H; Inoue T; Yamamura Y; Yabuuchi Y; Tanaka T
    J Clin Invest; 1993 Dec; 92(6):2653-9. PubMed ID: 8254021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solute-free water retention in preascitic cirrhotic rats following intravenous water loading.
    Sansoe G; Aragno M; Smedile A; Rizzetto M; Rosina F
    J Physiol Pharmacol; 2009 Dec; 60(4):111-7. PubMed ID: 20065504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.